The clinical outcomes of SARS-CoV-2 infection are various, including asymptomatic infection, mild upper respiratory tract illness, severe viral pneumonia, and even death. Īlthough the outbreak has been started from a primary zoonotic virus transmission in a large seafood market (Huanan Seafood Market), person-to-person transmission of the virus started a pandemic involving 197 countries. By January 7, 2020, Chinese scientists had isolated a novel virus belongs to coronaviruses family and classified it as a type of RNA virus. In December 2019, the first case of unknown origin pneumonia was identified in Wuhan, the capital city of Hubei Province. These results demonstrate the clinical, paraclinical, and imaging features of COVID-19. Among COVID-19 patients, 92% had a positive CT finding, most prevalently ground-glass opacification (GGO) (60%, 95% CI 58-62) and peripheral distribution opacification (64%, 95% CI 60-69). Increased CRP level, decreased lymphocyte count, and increased D-dimer level were the most common laboratory findings. Data for 3420 patients from 30 observational studies were included.
We did a systematic review and meta-analysis using three databases to identify clinical, laboratory, and computerized tomography (CT) scanning features of rRT-PCR confirmed cases of COVID-19.
Although clinical, laboratory, and imaging features of COVID-19 are characterized in some observational studies, we undertook a systematic review and meta-analysis to assess the frequency of these features. This virus expanded worldwide, causing global concern. An outbreak of pneumonia, caused by a novel coronavirus (SARS-CoV-2), was identified in China in December 2019.